A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Exploratory analysis of percentage of genomic loss of heterozygosity (LOH) in patients with platinum-sensitive recurrent ovarian carcinoma (rOC) in ARIEL3.
Ana Oaknin,Jonathan A. Ledermann,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W. Holloway,David M. O'Malley,Iain A. McNeish,Elizabeth M. Swisher,T. Cameron,Sandra Goble,James Sun,Kevin K. Lin,Robert L. Coleman +19 more
TL;DR: In ARIEL3, rucaparib significantly improved progression-free survival (PFS) vs placebo in all randomized patients, including patients with BRCa-mutant, BRCA wild-type/high-LOH (pres...
Journal ArticleDOI
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer.
Rachel Campbell,Daniel S.J. Costa,Martin R. Stockler,Yeh Chen Lee,Jonathan A. Ledermann,Dominique L. Berton,Jalid Sehouli,Felicia Roncolato,R. O. Connell,Aikou Okamoto,Jane Bryce,Amit M. Oza,Elisabeth Åvall-Lundqvist,Jonathan S. Berek,Anne Lanceley,Florence Joly,Felix Hilpert,A Feeney,Marie-Christine Kaminsky,Katrina Diamante,Michael Friedlander,Madeleine King +21 more
TL;DR: The Measure of Ovarian Symptoms and Treatment (MOST) concerns is a validated patient-reported symptom assessment tool for assessing symptom benefit and adverse effects of palliative chemotherapy in women with recurrent ovarian cancer (ROC) as mentioned in this paper .
Engot-ov16/nova: a phase 3 randomized double-blind trial of maintenance with parp-inhibitor niraparib versus placebo in patients with platinum-sensitive ovarian cancer.
M Mirza,Jonathan S. Berek,Ignace Vergote,Robert M. Wenham,J. M. Del Campo,Amit M. Oza,Sven Mahner,Bradley J. Monk,Michel Fabbro,Jonathan A. Ledermann,Christian Marth,Ilan Bruchim,Dionyssios Katsaros,Domenica Lorusso,Susanne Malander,Anne Dørum,Shefali Agarwal,Robert E. Martell,Ursula A. Matulonis +18 more
Journal ArticleDOI
Genomic characterization of long-term responders to olaparib.
Stephanie Lheureux,Jonathan A. Ledermann,Sarah Runswick,Darren Hodgson,Kirsten Timms,Jerry S. Lanchbury,Stanley B. Kaye,Charlie Gourley,David D.L. Bowtell,Elise C. Kohn,Clare L. Scott,Ursula A. Matulonis,Tony Panzarella,Brian Dougherty,J. Carl Barrett,Zhongwu Lai,Mark J. O'Connor,Jane Robertson,Tony W. Ho,Amit M. Oza +19 more
TL;DR: This study characterised long (LT ≥ 2 years) and short-term (ST ≤ 3months) responders on olaparib maintenance and tested the association between presence and absence of any factor comparing ST vs LT.
Journal ArticleDOI
Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.
Carol Aghajanian,Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W. Holloway,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Susana Banerjee,Kenton Wride,T. Cameron,Jonathan A. Ledermann +18 more
TL;DR: Rucaparib significantly improved progression-free survival (PFS) vs placebo in all primary analysis groups in ARIEL3 and this data indicates that this drug should be considered as a ‘breakthrough therapy’.